Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
4.020
-0.050 (-1.23%)
At close: Sep 22, 2026, 4:00 PM EDT
4.030
+0.010 (0.25%)
After-hours: Sep 22, 2026, 7:30 PM EDT
Seres Therapeutics Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Seres Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $17. The average 1-year stock price forecast is 322.89% higher than the current stock price, while the lowest is $12 (+198.51%) and the highest is $22 (+447.26%).
Price Target: $17 (+322.89%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Aug 6, 2026.
Analyst Ratings
The average analyst rating for Seres Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $22 | Buy | Maintains | $22 | +447.26% | Aug 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $12 | Buy | Reiterates | $12 | +198.51% | Aug 5, 2026 |
Financial Forecast
Revenue This Year
716.00K
from 789.00K
Decreased by -9.25%
Revenue Next Year
358.00K
from 716.00K
Decreased by -50.00%
EPS This Year
-4.36
from 0.64
EPS Next Year
-6.58
from -4.36
EPS and Forward PE are based on non-GAAP adjusted numbers.